Advertisement
Screening high-risk patients early may be the way to go
Researchers suspect that mutations may be leukemogenic
Taussig Cancer Institute chair picks most significant research
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Superior outcome for young adults on pediatric regimen
Combination therapy shows improved response in some
SGN-CD33A demonstrates encouraging antileukemic activity
Showcasing the latest science from Cleveland Clinic
Researchers hope findings will inspire multicenter trial
Results from Phase III CATCH trial add data to what was already a consensus-driven treatment option: low-molecular weight heparin.
Advertisement
Advertisement